Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
7330
Trial Sponsor
Trial Collaborator
Clinical Trial Start Date
2006
0Primary Completion Date
2009
0Study Completion Date
2009
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Intervention Name
Standard of care therapy0
Placebo0
Trovax0
Interventional Trial Phase
Phase 30
Participating Facility
Official Name
Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma0
Last Updated
October 19, 2020
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Triple0
Masked Party
Participant0
Care Provider0
Investigator0
Study summary
The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
